Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF) who ...

Please provide your email address to receive an email when new articles are posted on . A study of seven dialysis patients found that low doses of apixaban, an oral drug that more directly inhibits ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...

heart ecg arrhythmia For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

Recommendations around dosing, duration, and patient-specific options are woven into the fabric of the scientific statement.

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Eliquis (apixaban) is a prescription oral tablet used to reduce the risk of stroke in certain adults and to treat or prevent blood clots in certain adults and children. The Eliquis dosage you’re ...

Treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), regardless of dosage, was associated with significantly less major bleeding compared with warfarin in a particularly high-risk ...

The long-term adverse effects of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, are well ...